Featured Research

from universities, journals, and other organizations

MicroRNA targets identified in C. elegans

Date:
January 12, 2010
Source:
University of California - San Diego
Summary:
MicroRNAs (miRNAs) are noncoding RNAs that impact almost every aspect of biology. In recent years, they have been strongly implicated in stem cell biology, tissue and organism development, as well as human conditions ranging from mental disorders to cancer. Now, researchers have identified the binding sites of these miRNAs in one of the foremost model organisms, C. elegans, using biochemical means to capture targeted mRNA sequences in vivo.

MicroRNAs (miRNAs) are non-coding RNAs that impact almost every aspect of biology. In recent years, they have been strongly implicated in stem cell biology, tissue and organism development, as well as human conditions ranging from mental disorders to cancer. For the most part, miRNAs control gene expression of messenger RNA (mRNA) targets. Unlike mRNAs, which are translated into proteins, miRNAs function as short, untranslated molecules that regulate specific mRNAs through base-pairing interactions.

Since miRNAs bind limited stretches of consecutive bases in mRNAs, identifying which mRNAs are targets of individual miRNAs has been a bottleneck of biomedical research, as researchers have had to rely largely on computational predictions.

Now, researchers at the University of California, San Diego have identified the binding sites of these miRNAs in one of the foremost model organisms, C. elegans, using biochemical means to capture targeted mRNA sequences in vivo.

Argonaute proteins are key players in gene-silencing pathways; miRNAs are anchored into specific binding sites to guide Argonaute proteins to target mRNA molecules for silencing or destruction. By cross-linking interactions between the Argonaute protein bound to miRNA and mRNA duplexes, principal investigators Gene Yeo, PhD, assistant professor in UCSD's Department of Cellular and Molecular Medicine and Amy Pasquinelli, PhD, associate professor in UCSD's Division of Biological Sciences, were able to globally identify their specific binding sites in the nematode.

"Our results were very surprising in that we discovered that individual miRNAs can interact with their targets very differently, and differently than we had expected," said Yeo. "This approach, and the computational analyses that were develop, open up new ways to identify individual miRNA targets in any tissue and cell type in almost any organism."

"The revelation of thousands of endogenous miRNA target sites provides an unprecedented wealth of data for understanding how miRNAs regulate specific targets in a developing animal," added Pasquinelli.

Their work will be published online in advance of print on January 10 by Nature Structural & Molecular Biology.


Story Source:

The above story is based on materials provided by University of California - San Diego. Note: Materials may be edited for content and length.


Cite This Page:

University of California - San Diego. "MicroRNA targets identified in C. elegans." ScienceDaily. ScienceDaily, 12 January 2010. <www.sciencedaily.com/releases/2010/01/100110151327.htm>.
University of California - San Diego. (2010, January 12). MicroRNA targets identified in C. elegans. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/01/100110151327.htm
University of California - San Diego. "MicroRNA targets identified in C. elegans." ScienceDaily. www.sciencedaily.com/releases/2010/01/100110151327.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins